219 related articles for article (PubMed ID: 2050370)
1. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary.
Monteagudo C; Merino MJ; LaPorte N; Neumann RD
Hum Pathol; 1991 Apr; 22(4):368-72. PubMed ID: 2050370
[TBL] [Abstract][Full Text] [Related]
2. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens.
Fiel MI; Cernaianu G; Burstein DE; Batheja N
Acta Cytol; 1996; 40(4):637-41. PubMed ID: 8693878
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.
Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ
J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521
[TBL] [Abstract][Full Text] [Related]
4. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin.
Wick MR; Lillemoe TJ; Copland GT; Swanson PE; Manivel JC; Kiang DT
Hum Pathol; 1989 Mar; 20(3):281-7. PubMed ID: 2542151
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation.
Selim AA; El-Ayat G; Wells CA
Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein.
Ormsby AH; Snow JL; Su WP; Goellner JR
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013
[TBL] [Abstract][Full Text] [Related]
7. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
Tornos C; Soslow R; Chen S; Akram M; Hummer AJ; Abu-Rustum N; Norton L; Tan LK
Am J Surg Pathol; 2005 Nov; 29(11):1482-9. PubMed ID: 16224215
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of GCDFP-15 and GCDFP-24 in mammary and non-mammary tissue.
Satoh F; Umemura S; Osamura RY
Breast Cancer; 2000 Jan; 7(1):49-55. PubMed ID: 11029771
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.
Wallace ML; Longacre TA; Smoller BR
Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of estrogen/progesterone receptors and BRST-2 markers in metastatic ductal and lobular breast carcinoma to the skin.
Wallace ML; Smoller BR
Am J Dermatopathol; 1996 Jun; 18(3):241-7. PubMed ID: 8806958
[TBL] [Abstract][Full Text] [Related]
11. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
Raju U; Ma CK; Shaw A
Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
[TBL] [Abstract][Full Text] [Related]
12. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
13. [Serous cystadenocarcinoma of the ovary with simultaneous breast metastases. Description of a case].
Manini C; Pietribiasi F; Sapino A; Donadio S
Pathologica; 1998 Apr; 90(2):152-5. PubMed ID: 9619059
[TBL] [Abstract][Full Text] [Related]
14. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
15. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study with antibody to glycoprotein GCDFP-15 for metastatic lung cancer from breast cancer.
Nonami Y; Hisa S; Yamamoto A; Sasaguri S; Kiyoku H; Kurumaya H
J Cardiovasc Surg (Torino); 2001 Aug; 42(4):561-4. PubMed ID: 11455297
[TBL] [Abstract][Full Text] [Related]
17. Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors.
Mazoujian G; Bodian C; Haagensen DE; Haagensen CD
Cancer; 1989 Jun; 63(11):2156-61. PubMed ID: 2655863
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver.
Akasofu M; Kawahara E; Kurumaya H; Nakanishi I
Acta Pathol Jpn; 1993 Dec; 43(12):736-44. PubMed ID: 7509105
[TBL] [Abstract][Full Text] [Related]
19. Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients.
Matsuoka K; Ohsumi S; Takashima S; Saeki T; Aogi K; Mandai K
Breast Cancer; 2003; 10(4):330-4. PubMed ID: 14634511
[TBL] [Abstract][Full Text] [Related]
20. Mammary origin of metastases. Immunohistochemical determination.
Chaubert P; Hurlimann J
Arch Pathol Lab Med; 1992 Nov; 116(11):1181-8. PubMed ID: 1444749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
